Equibles does not estimate personal net worth.
Get an email with a short summary when Intensity Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get INTS alertsJoseph Talamo is recorded as CFO at Intensity Therapeutics, Inc. (INTS). The newest filing on record that lists Joseph Talamo as CFO at Intensity Therapeutics, Inc. (INTS) is dated April 30, 2026. Earlier roles on record: CFO at Lisata Therapeutics, Inc. (LSTA) until August 21, 2020. Intensity Therapeutics, Inc. reported in an 8-K filed December 12, 2023 that Joseph Talamo was appointed Chief Financial Officer, effective December 11, 2023. The proxy statement of Intensity Therapeutics, Inc. reports total compensation of $723,739 for Joseph Talamo in fiscal 2025, including a base salary of $374,696. Disclosed compensation is on record for 7 fiscal years. Joseph Talamo has spoken on 2 earnings calls across 2 companies, most recently for Intensity Therapeutics, Inc. on August 11, 2026. Those appearances were for Intensity Therapeutics, Inc. (INTS) and Lisata Therapeutics, Inc. (LSTA). Intensity Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Joseph Talamo spoke on are classified in the Healthcare sector. Other leadership on record at Intensity Therapeutics, Inc. includes Lewis H. Bender (CEO), Daniel Donovan (Board Member), Emer Leahy (Board Member) and 2 others.
“On December 11, 2023, Intensity Therapeutics (the "Company"), appointed Joseph Talamo to serve as the Chief Financial Officer of the Company effective December 11, 2023.”
“I am pleased to join you today to present a summary of our second quarter 2026 financial results. Our research and development expenses were $1.8 million for the second quarter of 2026, compared with $1.5 million for the same prior year period, reflecting an increase of $292,000, or 19%.”
“I'm pleased to provide a review of our first quarter financial results along with two notable funding events in April that significantly strengthen our balance sheet and extend our cash runway.”
Start not stated–present
Last confirmed April 30, 2026
Start not stated–2020-08-21
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Intensity Therapeutics, Inc. (INTS) | Chief Financial Officer | $374,696 | $723,739 |
| 2024 | Intensity Therapeutics, Inc. (INTS) | Chief Financial Officer | $370,000 | $1,662,576 |
| 2023 | Intensity Therapeutics, Inc. (INTS) | Chief Financial Officer | $14,231 | $456,371 |
| 2022 | Intensity Therapeutics, Inc. (INTS) | Chief Financial Officer | — | — |
| 2020 | Lisata Therapeutics, Inc. (LSTA) | Former Chief Financial Officer | $223,388 | $495,138 |
| 2019 | Lisata Therapeutics, Inc. (LSTA) | Former Chief Financial Officer | $338,077 | $676,630 |
| 2018 | Lisata Therapeutics, Inc. (LSTA) | Chief Financial Officer | $334,673 | $834,955 |
